Iqvia Hldgs Inc Stock Price, News & Analysis

IQVIA Holdings Inc. (NYSE:IQV) will report its third-quarter 2021 financial results on October 21, 2021, before market opening. A conference call is scheduled for 9:00 a.m. Eastern Time the same day, with details available on the IQVIA Investor Relations website. The earnings release and financial information will also be posted online. Participants need to register in advance to join the call. IQVIA is a global leader in advanced analytics and clinical research services, employing around 74,000 people across more than 100 countries.

IQVIA Holdings Inc. (NYSE:IQV) will host an Analyst and Investor Conference on November 16, 2021, in New York City. The conference will start at 10:00 a.m. ET and end around 12:30 p.m. ET. Management will provide a business update, and registration is required for attendance. The live event will be accessible via webcast, with login details available on the IQVIA Investor Relations website starting November 9, 2021. A replay will be available the same day.

IQVIA has announced the opening of a 160,000-square-foot facility for its Q² Solutions subsidiary in Research Triangle Park, North Carolina. This state-of-the-art lab will create up to 750 jobs over the next decade. The facility features advanced laboratory capabilities, including biomarker and genomics laboratories, and a Translational Science and Innovation Laboratory (TSAIL) to enhance drug development. These innovations aim to streamline R&D for biopharmaceutical companies, supporting faster drug development processes.

IQVIA has been selected by Polpharma Group to implement its Orchestrated Customer Engagement (OCE) platform across 12 countries in Central and Eastern Europe, including Poland and Russia. This strategic investment aligns with Polpharma's 2021-2025 growth strategy, aiming to enhance customer interactions and streamline operations. The OCE platform will improve salesforce productivity and expedite digital marketing campaigns using AI/ML capabilities. The collaboration is expected to strengthen Polpharma's market position and improve customer experience.

IQVIA announced a significant collaboration with NRx Pharmaceuticals to support pharmacovigilance and medical information for the potential emergency use authorization (EUA) of ZYESAMI, a treatment for COVID-19 patients. This partnership leverages IQVIA's extensive data and analytics capabilities to enhance compliance and support regulatory actions as the pandemic continues. NRx appreciates IQVIA's global reach, which will assist in delivering critical treatments to patients in need.

IQVIA has announced a strategic collaboration with HealthCore, Inc. to enhance real world evidence (RWE) studies in the U.S. The partnership aims to improve the quality and efficiency of RWE, which integrates data from electronic medical records, pharmacy claims, and patient-reported outcomes. The collaboration will focus on advancing research innovations, including external comparators and pragmatic trials, utilizing HealthCore’s extensive data sources. This initiative is expected to support better healthcare decision-making and patient outcomes, leveraging IQVIA's expansive analytics and technology capabilities.

IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2021 Global Healthcare Conference on September 14, 2021, at 12:15 p.m. EDT. A live audio webcast will be available on their website, with a replay accessible later that day. IQVIA is a global leader in analytics, technology solutions, and clinical research, operating in over 100 countries with approximately 74,000 employees. The company focuses on improving healthcare outcomes and patient privacy.

IQVIA (NYSE:IQV) has enhanced its Medical Information (MI) Contact Center services by integrating AI-powered technologies. This upgrade aims to improve response times and the overall experience for consumers, healthcare professionals (HCPs), and patients globally. The MI services now feature virtual agents working alongside human agents, enabling 24/7 support and efficient management of inquiries and adverse events. With operations in over 170 countries and support in 50 languages, IQVIA's advancements are set to bolster brand loyalty and trust in the life sciences industry.

IQVIA reported strong financial results for Q2 2021, with revenues of $3,438 million, a 36.4% increase year-over-year. Technology & Analytics Solutions revenue was $1,353 million, while Research & Development Solutions grew to $1,891 million, a 53.1% increase. The company's backlog rose to $23.9 billion, with an expected conversion of $6.6 billion into revenue. GAAP net income reached $175 million, compared to a loss last year. IQVIA raised its full-year guidance, estimating revenues of $13,550 - $13,700 million and adjusted diluted EPS of $8.70 - $8.90.